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Abstract
Purpose of Review The purpose of this study was to investigate the association of 26 inflammatory biomarkers (acute phase
proteins, cytokines, chemokines) and renal markers with coronary lipid core burden index (LCBI) assessed by near-infrared
spectroscopy (NIRS) imaging, as well as the association of these biomarkers with long-term cardiovascular outcome.
Recent Findings NIRS-derived LCBI has recently been shown to be an independent predictor of major adverse cardiac events
(MACE). However, studies on the association between circulating biomarkers and NIRS-derived characteristics have not yet
been performed.
Summary Between 2008 and 2011, 581 patients underwent diagnostic coronary angiography or percutaneous coronary inter-
vention for stable angina pectoris or acute coronary syndrome (ACS). NIRS of a non-culprit vessel was performed in a subset of
203 patients. In multivariable analyses, TNF-α tended to be associated with higher LCBI (beta 0.088 ln (pg/ml) increase per unit
LCBI; 95% CI 0.000–0.177, p = 0.05) after adjustment for clinical characteristics. However, this association did not persist after
Bonferroni correction (statistical threshold 0.0019). Major adverse cardiac events (MACE) were registered in 581 patients during
a median follow-up time of 4.7 years (IQR: [4.2–5.6] years). After adjustment for clinical characteristics and Bonferroni
correction, IL-8 (HR 1.60; 95%CI [1.18–2.17] per ln (pg/ml), p = 0.002) was borderline associated withMACE and significantly
associated with all-cause mortality or ACS (HR 1.75; 95% CI [1.24–2.48] per ln (pg/ml), p = 0.0015). In conclusion, we found
that IL-8 was independently associated with clinical outcome, but altogether, the multiplex panel we investigated here did not
render a useful blood biomarker of high LCBI.
This article is part of the Topical Collection on Global Coronary Heart
Disease
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Introduction
Vulnerable plaque, defined as a plaque that is sensitive to
rupture [1], is characterized by a large lipid core, thin fi-
brous cap, and active inflammation [2]. Pathology studies
have shown that approximately 60% of acute coronary syn-
dromes (ACS) are caused by ruptures of such vulnerable
plaques [3]. Near-infrared spectroscopy (NIRS) is a novel
catheter-based imaging technique based on diffuse reflec-
tance spectroscopy [4]. This technique is capable of char-
acterizing the chemical components of the atherosclerotic
plaque and is consequently able to identify lipid core [5•].
Lipid core plaques (LCP) have been shown to be more
vulnerable to rupture than non-LCP [6••, 7]. A strong asso-
ciation has been demonstrated between LCP, as detected by
NIRS, and cardiovascular events [6••].
An alternative, non-invasive way to detect LCP could
aid in risk stratification. Blood biomarkers may carry po-
tential to detect vulnerable plaques in an early stage and in a
non-invasive manner. Among others, biomarkers of inflam-
mation (such as acute phase proteins, cytokines, and
chemokines) and renal markers have strongly been impli-
cated in the atherosclerotic process and in the occurrence of
coronary events [7–12]. Currently, to the best of our knowl-
edge, there are no data available on the associations be-
tween circulating biomarkers and NIRS measurements.
Such an investigation could lead to further pathophysiolog-
ical insights concerning plaque vulnerability, and could
help bridge the gap between known biological pathways
and clinical imaging findings.
Therefore, the purpose of this study was to investigate the
association of 26 circulating inflammatory and renal bio-
markers with coronary lipid core burden index (LCBI) as de-
termined in vivo by NIRS imaging in patients undergoing
coronary angiography. Furthermore, the long-term prognostic
value of these biomarkers for the occurrence of major adverse
cardiac events (MACE) was evaluated.
Methods
Study Population and Design
The design of The European Collaborative Project on
Inflammation and Vascular Wall Remodel ing in
Atherosclerosis–Intravascular Ultrasound (ATHEROREMO-
IVUS), and its substudy the European Collaborative Project on
Inflammation and VascularWall Remodeling in Atherosclerosis–
Near-Infrared Spectroscopy (ATHEROREMO-NIRS), has been
described elsewhere [6••, 13•]. In brief, from2008 until 2011, 768
patients with an indication for diagnostic coronary angiography
(DCO) or percutaneous coronary intervention (PCI) due to stable
angina pectoris (SAP) or ACS were included in a biomarker
study in Erasmus MC, Rotterdam, the Netherlands. In 581 of
these patients, IVUS of a non-culprit vessel was performed
(Fig. 1). Among these patients, NIRS of the same segment was
performed in a subset of 191 patients. In 12 additional patients,
only NIRS, not IVUS, was performed, rendering a total of 203
patients in whom NIRS measurements were available.
Both studies were approved by the medical ethics commit-
tee of the Erasmus MC and were performed in accordance
with the criteria described in the declaration of Helsinki.
Written informed consent was obtained from all included
patients.
Biomarker Measurements
Blood samples were drawn from the arterial sheath prior to
the diagnostic coronary angiography or PCI procedure and
were stored at the clinical laboratory of Erasmus MC at a
temperature of − 80 °C within 2 h after blood collection. C-
reactive protein (CRP) was measured at Erasmus MC in
serum using an immunoturbidimetric high-sensitivity assay
(Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the
Cobas 8000 modular analyzer platform (Roche Diagnostics
Ltd., Rotkreuz, Switzerland). Frozen EDTA-plasma samples
were transported under controlled conditions (at a tempera-
ture of − 80 °C) to Myriad RBM, Austin, Texas, USA, where
the concentrations of cytokines, chemokines, acute-phase
proteins, and renal biomarkers were determined using a val-
idated multiplex assay (Custom Human Map, Myriad RBM,
Austin, Texas, USA). CRP, ferritin, haptoglobin, plasmino-
gen activator inhibitor 1 (PAI 1), fibrinogen, macrophage
inflammatory protein-1 alpha (MIP-1 α), macrophage in-
flammatory protein-1 beta (MIP-1 β), monocyte chemotac-
tic protein 1 (MCP-1), regulated upon activation normal T
cell expressed and secreted (Tcell-specific RANTES), tumor
necrosis factor receptor 2(TNF R2), interleukin-6 (IL-6),
interleukin-8 (IL-8), creatinine, cystatin C, adiponectin,
and myoglobin were determined in 570 patients from the
ATHEROREMO-IVUS population (n = 581) and 190 pa-
tients of the ATHEROREMO-NIRS population (n = 203).
Alpha-1-antitrypsin (AAT), alpha-2-macroglobulin
(A2Macro), complement C 3 (C3), tumor necrosis factor
alpha (TNF-α), tumor necrosis factor beta (TNF-β), inter-
feron γ (INF-γ), Interleukin-10 (IL-10), interleukin-18 (IL-
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18), neutrophil gelatinase-associated lipocalin (NGAL), and
beta-2-microglobulin (B2M) were determined in random
subsets of 473 and 156 patients, respectively. This difference
in numbers resulted from batch-wise handling of the samples
in combination with an update of the composition of the
multiplex assay by the manufacturer in-between two
batches. The biomarker laboratories had no knowledge of
clinical or intracoronary imaging data.
Near-Infrared Spectroscopy
The NIRS coronary imaging system consisted of a 3.2-F rapid
exchange catheter, a pullback and rotation device, and a console
(InfraReDx, Burlington, Massachusetts, USA). This NIRS sys-
tem was approved by the U.S. Food and Drug Administration.
The NIRS image acquisition was performed in a non-culprit
vessel. The order of preference for selection of the non-culprit
vessels was predefined in the study protocol: (1) left anterior
descending artery; (2) right coronary artery; and (3) left circum-
flex artery. The NIRS target segment of the non-culprit vessel
was required to be at least 40 mm in length and without signif-
icant luminal narrowing (< 50% stenosis) as assessed by online
angiography. Image acquisition was performed by a motorized
catheter pullback at a speed of 0.5 mm/s and 240 rpm in a
proximal segment of the artery, starting distal to a side branch.
Immediately after a pullback, the data in the scanned coronary
arterial segment were displayed in a chemogram. The probabil-
ity of the presence of LCP in the scanned coronary arterial
segment was calculated by means of a prediction algorithm
and was displayed using colors, ranging from red (low proba-
bility of LCP) to yellow-coded plaque (high probability of
LCP) [14] (Fig. 2). The x-axis of the chemogram represents
the pullback position in millimeters and the y-axis the degree
of rotation within the artery from 0 to 360°. The block
chemogram summarizes the chemogram in 2 mm increments.
The numeric value of each block in the block chemogram is the
90th percentile of all pixel values in the corresponding 2-mm
chemogram segment [15]. The block chemogram is mapped to
the same color scale as the chemogram, but the display is
binned to four discrete colors to aid in visual interpretation
(red: p < 0.57, orange: 0.57 < p ≤ 0.84, tan: 0.84 < p ≤ 0.98,
and yellow: p > 0.98, with p being the algorithm probability
that a LCP is present in that 2-mm block) [15]. The LCBI
quantifies the amount of LCP in the entire scanned artery seg-
ment on the block chemogram, and is computed as the fraction
of valid pixels that exceed an LCP probability of 0.6, multiplied
with 1000 [15]. NIRS images were evaluated offline by an
independent core research laboratory (Cardialysis BV,
Rotterdam, the Netherlands) that had no knowledge of any
other patient, biomarker, or outcome data.
Follow-up and Study Endpoints
Clinical and vital status of patients were collected from med-
ical charts, civil registries, or by written or telephone contact
with the patients or relatives. Specifically, all living patients
Fig. 1 Patient inclusion. IVUS of
a non-culprit artery was
performed in 581 patients and
blood samples were available in
570 patients. NIRS of a non-
culprit artery was performed in
203 patients and blood samples
were available in 190 patients
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participating in the IVUS/NIRS study were systematically
questioned on the occurrence of MACE and re-admission.
For patients with adverse events, hospital discharge letters
were obtained and treating physicians or hospitals were
contacted if necessary for additional information. The primary
endpoint was the occurrence of MACE, defined as the com-
posite of all-cause mortality, nonfatal ACS, or unplanned cor-
onary revascularization. The secondary endpoint was the
composite of all-cause mortality or nonfatal ACS.
Endpoints were adjudicated by a clinical events committee
that was blinded for biomarker data and IVUS/NIRS imaging
characteristics. ACS was defined as the clinical diagnosis of
ST segment elevation myocardial infarction (STEMI), non-
STEMI, or unstable angina pectoris (UAP) in accordance with
the guidelines of the European Society of Cardiology [16, 17].
Unplanned coronary revascularization was defined as un-
planned PCI or unplanned coronary artery bypass grafting
(CABG).
Statistical Analysis
The distributions of continuous variables, including bio-
markers and NIRS measurements, were examined for normal-
ity by visual inspection of the histogram and calculation of the
skewness coefficient. Normally distributed continuous vari-
ables are presented as mean ± standard deviation (SD), while
non-normally distributed continuous variables are presented
as median (interquartile range [IQR]) and were logarithmical-
ly (Ln) transformed for further analyses. For reasons of
uniformity, all biomarkers are presented as median (IQR).
Categorical variables are presented as numbers and percent-
ages. All analyses were performed in the full cohort and sub-
sequently in patients with ACS and patients with SAP sepa-
rately, to investigate possible heterogeneity.
We examined the association between biomarker concen-
trations and LCBI as assessed by NIRS using linear regression
with LCBI as the independent variable and continuous bio-
markers as the dependent variable. The concentrations of
CRP, A2Macro, ferritin, haptoglobin, PAI-1, MIP-1α, MIP-
1β, MCP-1, T cell-specific RANTES, TNF-α, TNF-β,
TNFR2, INF-γ, IL-6, IL-8, IL-10, IL-18, fibrinogen, creati-
nine, cystatin C, NGAL, adiponectin, myoglobin, and B2M
were not normally distributed and therefore Ln transformed.
TNF-β and IL-6 were too low to detect in a large part of the
patients and thus were not examined as continuous variables
but as categorical variables (measurable vs non-measurable).
The results are presented as beta coefficients (B) that indicate
unit increase in (Ln-transformed) biomarker per unit increase
in Ln-transformed LCBI measurement, with 95% confidence
intervals (CI).
Cox proportional hazards models were used to examine the
associations between biomarker concentrations and MACE,
as well as the composite of all-cause mortality or nonfatal
ACS. Results are presented as hazard ratios (HRs) per unit
increase in (Ln-transformed) biomarker concentration or per
category of biomarker concentration, with 95% CIs. Patients
lost to follow-up were considered at risk until the date of last
contact, at which time point they were censored. For patients
Fig. 2 Intracoronary near-infrared spectroscopy displayed as a
chemogram. The figure displays an example of coronary wall imaging
by near-infrared spectroscopy. Spectral characteristics of lipid core
plaques are displayed on a chemogram along the length (x-axis, in mm)
and circumference (y-axis, 0 to 360°) of the scanned coronary artery.
Yellow regions in the chemogram represent high probability of LCP
while red regions represent those with low probability of LCP. The
LCBI quantifies the amount of LCP in the entire scanned artery
segment on the block chemogram, and is computed as the fraction of
valid pixels that exceed an LCP probability of 0.6, multiplied with 1000
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with more than one event, the first was considered. To test
effect modification, interaction terms were entered into the
models consisting of the product of biomarker and indication
for angiography (ACS or SAP).
First, all above-described analyses were performed
univariably. Based on existing literature, age (continuous vari-
able), as well as sex, hypertension, hypercholesterolemia, and
diabetes mellitus (all categorical variables), were considered as
potential confounders and were subsequently entered as covar-
iates into the multivariable analyses. In the full cohort, indica-
tion for coronary angiography was also entered as a covariate.
All statistical tests were two-tailed. p values < 0.05 were
considered statistically significant and the results are present-
ed with 95% confidence intervals (95% CIs). Subsequently,
the Bonferroni correction was applied to account for the 26
biomarkers that were investigated (and thus p values < 0.05/
26, i.e., p < 0.0019, were considered statistically significant).
Data were analyzed with SPSS software (SPSS 23.0 IBM
Corp., Armonk, NY, USA).
Results
Baseline Characteristics
Baseline clinical and imaging characteristics are summarized in
Table 1 and Supplemental Table 1. In ATHEROREMO-NIRS
(n = 203), mean age was 63.4 years, and 72.9% were men. The
biomarker concentrations are presented in Supplemental Table
2 and Supplemental Table 3. In the full cohort (n = 570), serum
concentrations of MIP-1α, TNF-α, TNF-β, IL-6, and NGAL
were measurable in 84%, 92%, 8%, 38%, and 97% of the
patients, respectively. The remaining biomarker concentrations
were measurable in ≥ 99% of the patients. In the
ATHEROREMO-NIRS cohort, concentrations of TNF-β, IL-
6, and NGAL were measurable in 6%, 32%, and 96% of the
patients, respectively. The remaining biomarker concentrations
were measurable in ≥ 99% of the patients.
Association Between Coronary LCBI and Biomarkers
The results of the multivariable linear regression analy-
ses are depicted in Fig. 3 and Table 2. Higher TNF-α
(multivariable adjusted B 0.088 ln (pg/ml) per unit
LCBI; 95% CI 0.000–0.177, p = 0.05) displayed a ten-
dency towards an association at the p = 0.05 level with
higher LCBI in the full cohort after adjustment for clin-
ical characteristics. Effect estimates did not reach statis-
tical significance at the p = 0.05 level in ACS and SAP
patients (Fig. 3 and Table 2). After Bonferroni correction,
no associations were present between any of the bio-
markers and LCBI. Results of the univariable analyses
were materially the same (results not presented).
Biomarkers and Major Adverse Cardiac Events
Vital status was acquired for 569 out of 570 patients (99.8%).
The follow-up questionnaire assessing the occurrence of
MACE was completed by 87.5% of the 570 patients. During
a median follow-up time of 4.7 years IQR: [4.2–5.6] years,
155 patients (27%) experienced at least 1 MACE (primary
endpoint). Hazard ratios for the occurrence of MACE are
shown in Fig. 4 and Supplemental Tables 4a and 4b. After
Bonferroni correction, only IL-8 (p = 0.002) was borderline
significantly associated with MACE. No independent associ-
ations were present between the other biomarkers andMACE.
At the p = 0.05 level, some biomarkers tended to display as-
sociations with MACE. Specifically, on univariable analysis,
higher T cell-specific RANTES, IFN-ɣ, IL-8, cystatin C, and
B2Mwere associated with a higher incidence of MACE at the
p = 0.05 level. After adjustment for clinical characteristics,
IFN-ɣ (HR 1.57; 95% CI [1.10–2.23 per ln (pg/ml)) and IL-
8 (HR 1.60; 95% CI [1.18–2.17 per ln (pg/ml)) remained
independently associated with MACE at the p = 0.05 level.
Interaction terms between biomarkers and indication for angi-
ography only reached significance for IL-10 (p for interac-
tion = 0.05). In patients diagnosed with ACS or SAP, there
were no significant associations between any of the bio-
markers and MACE.
Only IL-8 (p = 0.0015) was significantly associated with
the composite of death or ACS (secondary endpoint) after
Bonferroni correction and adjustment for clinical characteris-
tics (Supplemental Table 5). At the p = 0.05 level, higher CRP,
A2Macro, fibrinogen, TNFR2, INF-γ, IL-8, cystatin C,
adiponectin, and B2M were associated with this secondary
endpoint on univariable analysis (data not shown).
Interaction terms between biomarkers and indication for angi-
ography reached significance for B2M (p for interaction =
0.036). In patients with ACS, only IL-8 (HR 2.89; 95%CI
[1.86–4.14 per ln (pg/ml) p ≤ 0.001) remained associated with
the composite of death or ACS after multivariable adjustment
and Bonferroni correction. In patients with SAP, the HR for
IL-8was closer to the null (HR 1.12; 95%CI [0.61–2.03 per ln
(pg/ml) p = 0.72). Effect estimates for CRP and INF-γ were
similar to those in the full cohort in ACS and SAP patients, but
statistical significance was not reached. For B2M, the multi-
variable adjusted hazard ratio was significantly higher in SAP
patients than in ACS patients, but did not reach statistical
significance after Bonferroni correction.
Discussion
We investigated the association of 26 circulating biomarkers
with NIRS-derived LCBI in 203 patients undergoing coronary
angiography. After multivariable adjustment and correction
for multiple testing, none of the 26 biomarkers was associated
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with LCBI. Furthermore, we also investigated the long-term
prognostic value of these 26 biomarkers for clinical cardiovas-
cular outcome in 570 patients. After correction for multiple
testing, we found that IL-8 was borderline significantly asso-
ciated with MACE and independently associated with death
or ACS.
Studies on the association between circulating biomarkers
and NIRS-derived characteristics have not been performed
previously. NIRS has recently progressed from bench testing
to human studies. In 1993, Cassis and Lodder [18] first
described the use of NIRS for characterization of atheroscle-
rotic plaque in rabbit aortas. Ever since, there have been sev-
eral [4, 15] studies that have validated the use of NIRS for
identification of lipid deposition within the coronary arteries.
NIRS has been shown to identify extensive LCPs that are
associated with a high risk of peri-procedural myocardial in-
farction [15]. In our previous report on the current study pop-
ulation, NIRS-derived LCBI was an independent predictor of
MACE during 1 year follow-up [6••]. As NIRS has the poten-
tial to identify LCPs indicative of plaque vulnerability in the
Table 1 Baseline clinical and
procedural characteristics
(ATHEROREMO-NIRS cohort,
n = 203)
Total ACS patients SAP patients
(n = 203) (n = 95) (n = 108)
Clinical characteristics
Age, years, mean ± standard deviation 63.4 ± 10.9 62 ± 11.7 64.7 ± 10.2
Male 148(72.9) 63(66.3) 85(78.7)
Diabetes mellitus 41(20.2) 17(17.9) 24(22.2)
Hypertension 114(56.2) 51(53.7) 63(58.3)
Hypercholesterolemia 115(56.7) 43(45.3) 72(66.7)
Smoking 50(24.6) 30(31.6) 20(18.5)
Positive family history of CAD 120(59.1) 51(54.3) 69(63.9)
Previous MI 79(38.9) 34(35.8) 45(41.7)
Previous PCI 78(38.4) 27(28.4) 51(47.2)
Previous CABG 6(3.0) 2(2.1) 4(3.7)
Previous stroke 6(3.0) 4(4.2) 2(1.9)
Peripheral artery disease 11(5.4) 5(5.3) 6(5.6)
History of heart failure 9(5.9) 3(3.2) 6(5.6)
Procedural characteristics
Indication for coronary angiography
ACS 95(46.8) 95(100) –
Acute MI 28(13.8) 28(29.5) –
Unstable angina pectoris 67(33.0) 67(70.5) –
Stable angina pectoris 108(53.2) – 108(100)
PCI performed 179(88.2) 88(92.6) 91(84.3)
Coronary artery disease1
No significant stenosis 16(7.9) 8(8.4) 8(7.4)
1-vessel disease 106(52.2) 49(51.6) 57(52.8)
2-vessel disease 58(28.6) 26(27.4) 32(29.6)
3-vessel disease 23(11.3) 12(12.6) 11(10.2)
NIRS characteristics
Median LCBI [IQR] 43.0[15.0–90.0] 47.0[16.0–90.0] 35.0[14.0–85.5]
Imaged coronary artery
Left anterior descending 74(36.5) 41(43.2) 33(30.6)
Left circumflex 70(34.5) 30(31.6) 40(37.0)
Right coronary artery 59(29.1) 24(25.3) 35(32.4)
Continuous variables are presented as mean ± standard deviation (SD) or median [IQR]. Categorical variables are
presented in numbers (n) and percentages (%). ACS, acute coronary syndrome; CABG, coronary artery bypass
grafting; CAD, coronary artery disease; IQR, interquartile range; LCBI, lipid core burden index; MI, myocardial
infarction; PCI, percutaneous coronary intervention; SAP, stable angina pectoris
1 A significant stenosis was defined as a stenosis ≥50% of the vessel diameter by visual assessment of the coronary
angiogram
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coronary arteries, we hypothesized that circulating inflamma-
tory biomarkers are associated with NIRS-derived LCBI.
However, we could not demonstrate any associations between
these biomarkers and NIRS-derived LCBI after Bonferroni
correction. These results suggest that any potential effects of
these biomarkers on atherosclerosis are exerted through other
mechanisms.
TNF-α is a pro-inflammatory cytokine with pleiotropic
actions. In a previous report on the current patient population,
TNF-α concentration was positively associated with plaque
burden and plaque vulnerability as determined by IVUS [8].
In the current study, we found that at the p = 0.05 level,
TNF-α displayed a tendency towards a positive association
with LCBI after multivariable adjustment, but this association
did not persist after correction for multiple testing. Previously,
Sukhija et al. [19] found no association between serumTNF-α
levels and extent of atherosclerosis or clinical outcome
in patients with known coronary artery disease (CAD).
Conversely, other studies [20, 21] have demonstrated positive
associations between plasma concentration of TNF-α and cor-
onary events. However, in our study, TNF-α was not associ-
ated with MACE at long-term follow-up, implying that the
deleterious effect of TNF-α, if any, does not translate into a
higher MACE rate in the current study population. More re-
search is necessary to further substantiate the pathological
mechanisms underlying the roles of this biomarker in athero-
sclerotic plaque development. No associations could be dem-
onstrated between any of the other biomarkers and NIRS-
derived LCBI.
In our previous reports on the ATHEROREMO-IVUS
study [8–12], levels of CRP, ferritin, RANTES, TNF-α, IL-
10, cystatin C, and NGAL were associated with IVUS-VH-
derived plaque burden in the full cohort. Additionally, IL-10,
cystatin C, and NGAL were associated with IVUS-VH-
derived thin-cap fibroatheroma (VH-TCFA) lesions. This dif-
ference in findings could in part be explained by the
Fig. 3 Association of 26 biomarkers with LCBI in the full NIRS cohort
and in patients with ACS or SAP. Results are presented as betas which
signify unit increase in (Ln-transformed) biomarker concentration or in
category of biomarker concentration, per unit increase in Ln-transformed
LCBI measurement, with 95% confidence intervals (CI)
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Table 2 Association between biomarkers and LCBI (NIRS cohort n = 203)
Total (n = 203) ACS patients (n = 95) SAP patients (n = 108)
B [95% CI]1 p value B [95% CI]2 p value B [95% CI]2 p value
Acute phase proteins
CRP3 0.165 (−0.007–0.337) 0.06 0.224 (−0.023–0.471) 0.08 0.071 (−0.164–0.307) 0.55
AAT4 −0.025 (−0.071–0.022) 0.30 −0.017 (−0.087–0.054) 0.64 −0.043 (−0.107–0.021) 0.18
A2Macro5 −0.013 (−0.040–0.014) 0.35 0.001 (−0.040–0.043) 0.95 −0.031 (−0.065–0.004) 0.08
Complement C35 −0.005 (−0.031–0.021) 0.72 −0.020 (−0.059–0.019) 0.32 0.018 (−0.019–0.054) 0.34
Ferritin5 −0.022 (−0.129–0.086) 0.69 0.060 (−0.096–0.215) 0.45 −0.096 (−0.249–0.058) 0.22
Haptoglobin6 0.022 (−0.023–0.067) 0.34 0.025 (−0.044–0.095) 0.47 0.015 (−0.046–0.076) 0.62
PAI 16 0.041 (−0.029–0.111) 0.25 0.029 (−0.078–0.136) 0.59 0.040 (−0.054–0.134) 0.40
Fibrinogen6 −0.005 (−0.039–0.030) 0.79 −0.015 (−0.070–0.039) 0.58 0.006 (−0.038–0.051) 0.78
Chemokine
MIP-1 α6 0.006 (−0.056–0.067) 0.86 0.036 (−0.047–0.118) 0.39 −0.035 (−0.127–0.056) 0.44
MIP-1 β6 0.015 (−0.040–0.070) 0.60 −0.008 (−0.086–0.069) 0.83 0.033 (−0.048–0.113) 0.42
MCP-16 0.015 (−0.037–0.066) 0.57 −0.041 (−0.116–0.034) 0.28 0.062 (−0.008–0.131) 0.08
T cell-specific RANTES6 0.039 (−0.058–0.136) 0.43 0.028 (−0.118–0.173) 0.71 0.038 (−0.099–0.175) 0.59
Cytokines
TNF-α5 0.088 (0.000–0.177) 0.05 0.043 (−0.075–0.161) 0.47 0.128 (−0.005–0.262) 0.06
TNF-β6 −0.007 (−0.039–0.026) 0.68 0.001 (−0.035–0.038) 0.94 −0.026 (−0.083–0.032) 0.37
TNF R26 0.011 (−0.028–0.049) 0.59 −0.025 (−0.080–0.029) 0.36 0.047 (−0.008–0.101) 0.09
IFN-ɣ5 0.029 (−0.042–0.100) 0.42 0.037 (−0.055–0.128) 0.42 −0.007 (−0.117–0.103) 0.90
IL-66 0.018 (−0.034–0.071) 0.49 0.003 (−0.076–0.082) 0.94 0.031 (−0.041–0.103) 0.39
IL-86 0.034 (−0.021–0.090) 0.23 0.022 (−0.056–0.100) 0.57 0.041 (−0.040–0.121) 0.32
IL-105 −0.023 (−0.125–0.079) 0.65 0.009 (−0.132–0.149) 0.90 −0.048 (−0.205–0.109) 0.55
IL-185 −0.015 (−0.070–0.041) 0.61 −0.005 (−0.094–0.085) 0.92 −0.023 (−0.095–0.048) 0.52
Renal markers
Creatinine7 0.004 (−0.024–0.032) 0.77 0.011 (−0.035–0.057) 0.64 −0.001 (−0.035–0.034) 0.96
Cystatin C6 0.011 (−0.016–0.039) 0.42 0.002 (−0.040–0.045) 0.91 0.026 (−0.012–0.064) 0.17
NGAL5 0.062 (−0.016–0.139) 0.12 0.048 (−0.049–0.145) 0.33 0.070 (−0.055–0.196) 0.27
Other markers
Adiponectin6 0.005 (−0.065–0.075) 0.87 0.028 (−0.074–0.131) 0.59 −0.021 (−0.122–0.079) 0.67
Myoglobin6 −0.096 (−0.207–0.015) 0.09 −0.120 (−0.302–0.061) 0.19 −0.042 (−0.176–0.091) 0.53
B2M5 −0.010 (−0.063–0.043) 0.72 −0.064 (−0.135–0.007) 0.08 0.059 (−0.023–0.140) 0.15
Variables with a non-normal distribution were transformed by the natural logarithm (ln). Results are presented as beta coefficients (B) that indicate unit
increase in (ln-transformed) biomarker level or in category of biomarker concentration, per unit Ln-transformed LCBI, with 95% confidence intervals
(CI)
AAT, alpha-1-antitrypsin; ACS, acute coronary syndrome; A2Macro, alpha-2-Macroglobulin; B2M, beta-2-microglobulin; CRP, C-reactive protein; IFN-
ɣ, interferon ɣ; IL, interleukin; IQR, interquartile range; LCBI, lipid core burden index; MCP-1, monocyte chemotactic protein 1; MI, myocardial
infarction; MIP-1α, macrophage inflammatory protein-1 alpha; MIP-1β, macrophage inflammatory protein-1 beta; NGAL, neutrophil gelatinase-asso-
ciated lipocalin; PAI 1, plasminogen activator inhibitor 1; RANTES, regulated upon activation normal T cell expressed and secreted; SAP, stable angina
pectoris; TNF-α, tumor necrosis factor alpha; TNF-β, tumor necrosis factor beta; TNF R2,tumor necrosis factor receptor 2
1Model is adjusted for age, gender, diabetes mellitus, hypertension, hypercholesterolemia, and indication for coronary angiography
2Models are adjusted for age, gender, diabetes mellitus, hypertension, and hypercholesterolemia
3Available in the full cohort
4 Available in 156 patients
5 Available in 190 patients
6 Too low to detect in a large part of the patients (TNF-β was measurable in 6% and IL 6 in 32% of the patients) and thus not examined as a continuous
variable but as a categorical variable (measurable vs not measurable)
7 Available in 188 patients
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differences in definitions used for NIRS- and IVUS-derived
measures of plaque vulnerability. NIRS-derived LCBI repre-
sents the amount of LCP in the entire scanned artery segment,
and is computed as the fraction of valid pixels on the block
chemogram that exceed an LCP probability of 0.6, multiplied
with 1000. IVUS-VH-derived TCFA lesions are defined as
lesions with presence of > 10% confluent necrotic core in
direct contact with the lumen [9]. Although these entities are
related, previous studies have shown that the correlation be-
tween LCP as detected by NIRS and necrotic core as detected
by IVUS-VH is weak [14].
We found that IL-8 is associated with clinical outcome
during long-term follow-up. Inoue T. et al. [22] investigated
the long-term prognostic value of IL-8 in patients with CAD
and found IL-8 as only cytokine predictor of cardiovascular
events, independently of other cytokines and hs-CRP.
Cavusoglu et al. [23] found an association between high base-
line plasma levels of IL-8 with increased risk of long-term all-
cause mortality in patients with ACS. Our findings are in line
with these results.
Study Limitations
This study has several limitations. First, this is a cross-
sectional study. As we did not repeat NIRS imaging of the
same segment at a later time point, no information is available
on the change in LCBI and its relation with biomarkers levels
over time. Future researchmight focus on the effects of chang-
es in biomarker level and their effect on LCBI. Secondly, the
NIRS image acquisition was performed in only one non-
culprit vessel. This study design was chosen based on the
hypothesis that such a non-stenotic segment reflects coronary
wall pathophysiology in the larger coronary tree [13•]. This
assumption, on its part, was based on the fact that ex vivo, as
well as in vivo, studies in patients with myocardial infarction,
have demonstrated presence of TCFA (as assessed by IVUS)
located elsewhere than the culprit lesion or even culprit artery
[8–12]. In fact, we were subsequently able to confirm this
hypothesis, by demonstrating that NIRS imaging characteris-
tics of the non-culprit artery are associated with increased risk
of MACE [6••].
Fig. 4 Association of 26 biomarkers withMACE in the full cohort and in patients with ACS or SAP. Results are presented as hazard ratios (HRs) per unit
increase in (Ln-transformed) biomarker concentration or per category of biomarker concentration, with 95% confidence intervals (CI)
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Conclusion
None of the 26 biomarkers we examined was associated with
LCBI after correction for multiple testing. IL-8 was associated
with clinical outcome in patients undergoing coronary angi-
ography after correction for multiple testing. Altogether, the
multiplex panel we investigated here did not render a useful
blood biomarker of high LCBI.
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